Positive tests for non-prescribed use of fentanyl and opioids, as well as heroin, increased during the early months of the COVID-19 pandemic, according to a recently published study of nearly 900,000 de-identified lab results conducted by Quest Diagnostics. Use of fentanyl in combination with other drugs also surged.
The addition of recovery coaching and the use of a digital breathalyzer test were found to reduce participant attrition rates in an outpatient SUD treatment program.
A speaker at this spring's Rx Drug Abuse & Heroin Summit discusses the latest national data on emerging drug threats, highlighting the need to focus on stimulant trends.